The Baltimore plant has been contracted to manufacture the Johnson & Johnson vacuum against the covid-19 stable sucia, does not apply the production protocols and staff to establish capacity, which is used in material contamination for injections, revealing the miracles the regulators estadounidenses.
La Food and Drug Administration (FDA for its seals in English) issues information about its recent inspection of the Emergent Biosciences factory, which has paralyzed production.
The inspectors will find that a lot of the substance used for the J&J vaccine, which requires a single injection, establishes contaminated material used for the vaccines against the covid-19 of another customer of the company, AstraZeneca. It would be necessary to dispose of all these lots, provided that the information is sufficient to produce a 15 million dose of the J&J vaccine.
The European Medicines Agency has found a “possible corner” between the vaccine and rare cases of coagulation detection detected in the United States
The information mentions other problems, such as unpainted paint, black residues and piss on floors and walls, deficient glue and implements that do not apply the protocols to avoid contamination.
Emergent and Johnson & Johnson are pushing for more solutions to the mayor’s problems. At this time, none of the products manufactured by J&J have been distributed.
The use of the J & J’s vacancy is paused in the United States at the moment while the authorities are investigating its relationship with very rare bloodthirsty coyotes. Use 8 million doses of this vaccine, coming from Europe.
WASHINGTON – United States has taken steps to renew the covid-19 vacancy application
The Baltimore plant detonates the production of fines taken every week by the FDA. The agency does not have the emergency authorization for the factory, necessary to be able to distribute its products.
The FDA believes that the product produced by Emergent is in deposit, in the form of additional tests.